LL-37 is a naturally occurring human antimicrobial peptide with broad health benefits, primarily centered on immune defense, infection control, and tissue repair. 
Antimicrobial Action: LL-37 fights a wide range of pathogens, including bacteria (e.g., MRSA, E. coli, Staphylococcus aureus), viruses (e.g., influenza, herpes), fungi (e.g., Candida), and biofilms, using a membrane-disrupting mechanism that reduces the risk of resistance. 
Immune Modulation: It balances immune responses by recruiting immune cells, reducing pro-inflammatory cytokines, and promoting anti-inflammatory signals, helping to resolve chronic inflammation without overstimulation. 
Wound Healing & Skin Repair: LL-37 accelerates healing by promoting angiogenesis, epithelial cell migration, collagen deposition, and re-epithelialization, making it beneficial for diabetic ulcers, burns, surgical wounds, and chronic skin conditions like eczema and acne. 
Gut Health: Expressed in the gastrointestinal tract, it supports gut barrier integrity, reduces intestinal inflammation, and aids in recovery from leaky gut, IBD, and post-infection damage, especially when stacked with peptides like BPC-157. 
Inflammation and Autoimmune Support: While elevated levels can contribute to autoimmunity (e.g., psoriasis, lupus), controlled LL-37 therapy can suppress excessive immune activation and promote tissue healing in immune-dysregulated conditions when used under clinical guidance. 
Chronic Infection Management: Effective against biofilm-associated infections such as chronic Lyme disease, recurrent UTIs, and sinusitis, where conventional antibiotics fail. 
LL-37 is used clinically via subcutaneous injection, topical gel, or intranasal delivery, often in combination with other peptides like BPC-157 or KPV for synergistic healing effects.  It is not FDA-approved for human use but is available by prescription in integrative medicine settings.